

References for www.calprotectin.com

1. Inciarte-Mundo, J., B. Frade-Sosa, and R. Sanmartí, From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. *Front Immunol*, 2022. 13: p. 1001025.
2. Wang, Q., W. Chen, and J. Lin, The Role of Calprotectin in Rheumatoid Arthritis. *Journal of translational internal medicine*, 2019. 7(4): p. 126-131.
3. Pruenster, M., et al., S100A8/A9: From basic science to clinical application. *Pharmacol Ther*, 2016. 167: p. 120-131.
4. Ometto, F., et al., Calprotectin in rheumatic diseases. *Experimental biology and medicine (Maywood, N.J.)*, 2017. 242(8): p. 859-873.
5. Romano, M., et al., The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. *Ann Rheum Dis*, 2022. 81(7): p. 907-921.
6. Fautrel, B., et al., EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. *Ann Rheum Dis*, 2024.
7. Anink, J., et al., MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. *Arthritis Res Ther*, 2015. 17(1): p. 200.
8. La, C., et al., Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. *RMD Open*, 2021. 7(2).
9. Foell, D., et al., Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. *Jama*, 2010. 303(13): p. 1266-73.
10. Sumner, E.J., et al., Use of MRP8/14 in clinical practice as a predictor of outcome after methotrexate withdrawal in patients with juvenile idiopathic arthritis. *Clin Rheumatol*, 2022. 41(9): p. 2825-2830.
11. Park, C., et al., MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. *Rheumatology (Oxford)*, 2021.
12. Jarlborg, M., et al., Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. *Arthritis research & therapy*, 2020. 22(1): p. 105-105.
13. Hurnakova, J., et al., Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. *PloS one*, 2017. 12(8): p. e0183420-e0183420.
14. Bae, S.C. and Y.H. Lee, Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. *Postgrad Med*, 2017. 129(5): p. 531-537.
15. Torgutalp, M., et al., Serum Calprotectin is Indicating Clinical and Ultrasonographic Disease Activity in Rheumatoid Arthritis, even with Normal C-Reactive Protein Levels. *Mediterr J Rheumatol*, 2021. 32(1): p. 56-65.
16. Wang, Y. and Y. Liang, Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein. *Int J Clin Exp Pathol*, 2019. 12(3): p. 1009-1014.
17. Hurnakova, J., et al., Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. *Clin Rheumatol*, 2018. 37(8): p. 2055-2062.
18. Inciarte-Mundo, J., et al., Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. *Arthritis research & therapy*, 2018. 20(1): p. 275-275.
19. d'Angelo, D.M., et al., Serum calprotectin and joint ultrasound in the definition of disease relapse in non-systemic juvenile idiopathic arthritis: a prospective longitudinal study. *Clin Exp Rheumatol*, 2023.
20. Frade-Sosa, B., et al., Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors. *Ther Adv Musculoskelet Dis*, 2022. 14: p. 1759720x221114105.
21. Gernert, M., et al., Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy. *Arthritis Res Ther*, 2022. 24(1): p. 200.
22. Srsen, S., et al., Serum Levels of S100A8/A9 as a Biomarker of Disease Activity in Patients with IgA Vasculitis. *Biomedicines*, 2024. 12(4).
23. Hirono, K., et al., Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. *J Am Coll Cardiol*, 2006. 48(6): p. 1257-64.
24. Lech, M., et al., Circulating Markers of Inflammation Persist in Children and Adults With Giant Aneurysms After Kawasaki Disease. *Circ Genom Precis Med*, 2019. 12(4): p. e002433.
25. Hoshino, S., et al., Biomarkers of inflammation and fibrosis in young adults with history of Kawasaki disease. *Int J Cardiol Heart Vasc*, 2021. 36: p. 100863.

WE INNOVATE DIAGNOSTIC EFFICIENCY

Contact information: marketing@gentian.com • www.gentian.com

gentian